ArticleThe Lancet regional health. Europe2021

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany.

Bjoern Jensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.